{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:24:58Z","timestamp":1787585098833,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"DOI":"10.7759\/cureus.115086","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:42:14Z","timestamp":1787582534000},"source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Mohmed Sohel","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Bhanu","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant M","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesha H","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Type 2 diabetes","author":"Goyal R","unstructured":"Goyal R, Singhal M, Jialal I. Type 2 diabetes. StatPearls. StatPearls (ed): StatPearls Publishing, Treasure Island, FL;"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton IM","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al.. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321:405-12. 10.1136\/bmj.321.7258.405","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X1604201229115531","article-title":"Complications of the type 2 diabetes mellitus","volume":"16","author":"Farmaki P","year":"2020","unstructured":"Farmaki P, Damaskos C, Garmpis N, Garmpi A, Savvanis S, Diamantis E. Complications of the type 2 diabetes mellitus. Curr Cardiol Rev. 2020, 16:249-51. 10.2174\/1573403X1604201229115531","journal-title":"Curr Cardiol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi I","year":"2026","unstructured":"Genitsaridi I, Salpea P, Salim A, et al.. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes & Endocrinology. 2026, 14:149-56. 10.1016\/S2213-8587(25)00299-2","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.04.010404","article-title":"Urbanization and prevalence of type 2 diabetes in Southern Asia: a systematic analysis","volume":"4","author":"Cheema A","year":"2014","unstructured":"Cheema A, Adeloye D, Sidhu S, Sridhar D, Chan KY. Urbanization and prevalence of type 2 diabetes in Southern Asia: a systematic analysis. J Glob Health. 2014, 4:010404. 10.7189\/jogh.04.010404","journal-title":"J Glob Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner RC","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999, 281:2005-12. 10.1001\/jama.281.21.2005","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes - 2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes - 2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo RA","year":"2009","unstructured":"Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58:773-95. 10.2337\/db09-9028","journal-title":"Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola D","year":"2015","unstructured":"Sola D, Rossi L, Schianca GP, et al.. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015, 11:840-8. 10.5114\/aoms.2015.53304","journal-title":"Arch Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S33194","article-title":"Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]","volume":"8","author":"Basit A","year":"2012","unstructured":"Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012, 8:463-72. 10.2147\/HIV.S33194","journal-title":"Vasc Health Risk Manag"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903512955","article-title":"The role of glimepiride in the treatment of type 2 diabetes mellitus","volume":"6","author":"Briscoe VJ","year":"2010","unstructured":"Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010, 6:225-35. 10.1517\/17425250903512955","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon V","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017, 60:215-25. 10.1007\/s00125-016-4157-3","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck MA","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, Dur\u00e1n-Garc\u00eda S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011, 34:2015-22. 10.2337\/dc11-0606","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12239","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis","volume":"16","author":"Goring S","year":"2014","unstructured":"Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014, 16:433-42. 10.1111\/dom.12239","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15164","article-title":"Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study","volume":"25","author":"Park HK","year":"2023","unstructured":"Park HK, Kim KA, Min KW, et al.. Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study. Diabetes Obes Metab. 2023, 25:2743-55. 10.1111\/dom.15164","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref21","article-title":"Glimepiride","author":"Trerattanavong K","year":"2026","unstructured":"Trerattanavong K, Tadi P. Glimepiride. StatPearls. StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey CJ","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013, 11:43. 10.1186\/1741-7015-11-43","journal-title":"BMC Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson KM","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013, 27:473-8. 10.1016\/j.jdiacomp.2013.05.004","journal-title":"J Diabetes Complications"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516304-a-comparative-evaluation-of-dapagliflozin-and-sulfonylureas-in-patients-with-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:42:14Z","timestamp":1787582534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516304-a-comparative-evaluation-of-dapagliflozin-and-sulfonylureas-in-patients-with-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.115086","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}